What is Neuropace, Inc.'s D&A?

Neuropace, Inc. (NPCE) reported D&A of $60K in Q1 2026.

How has Neuropace, Inc.'s D&A changed year-over-year?

Neuropace, Inc.'s D&A increased by 22.4% year-over-year, from $49K to $60K.

What is the long-term trend for Neuropace, Inc.'s D&A?

Over 4 years (2021 to 2025), Neuropace, Inc.'s D&A has grown at a -1.7% compound annual growth rate (CAGR), from $353K to $329K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Neuropace, Inc. NPCE D&A

D&A at other companies

MedtronicMDT

$716M-14.8%

LivaNovaLIVN

$8.3M+29.3%

ClearPoint NeuroCLPT

$86K-16.5%

Inspire Medical SystemsINSP

$5.11M+67.9%

ARS Pharmaceuticals, Inc.SPRY

$397K+41.8%

Catalyst PharmaceuticalCPRX

$70K-39.1%

Other financials

Income statement

See full

Revenue$22.1M-2.0%

Gross profit$18.0M+4.1%

Operating income-$5.6M-8.2%

Net income-$6.7M-1.5%

EPS (diluted)-$0.20+4.8%

Balance sheet

See full

Cash & equivalents$15.6M-42.4%

Total debt$70.5M-3.7%

Total equity$14.5M-40.4%

Total assets$98.9M-10.3%

Cash flow

See full

Operating cash flow-$5.9M+21.1%

CapEx$117.0K+216%

Free cash flow-$6.0M+20.0%

Valuation

See full

Market cap$557.77M+63.4%

Enterprise value$612.6M+58.1%

P/S5.6×+1.6×

Profitability

See full

Gross margin78.3%+3.5pp

Operating margin-16.8%-3.5pp

Net margin-21.7%-4.5pp

FCF margin-10.3%-3.5pp

Returns & leverage

See full

Return on equity-111.4%-13.1pp

Debt / equity4.9×+1.9×

Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neuropace, Inc.'s D&A?: Neuropace, Inc. (NPCE) reported D&A of $60K in Q1 2026.
How has Neuropace, Inc.'s D&A changed year-over-year?: Neuropace, Inc.'s D&A increased by 22.4% year-over-year, from $49K to $60K.
What is the long-term trend for Neuropace, Inc.'s D&A?: Over 4 years (2021 to 2025), Neuropace, Inc.'s D&A has grown at a -1.7% compound annual growth rate (CAGR), from $353K to $329K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.